SAB Biotherapeutics, Inc. (SABS)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
SAB Biotherapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →SAB Biotherapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →SAB Biotherapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for SAB Biotherapeutics, Inc. in this window.
People at SAB Biotherapeutics, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for SAB Biotherapeutics, Inc..